Research Article | Open Access
Aloperine Protects Mice against DSS-Induced Colitis by PP2A-Mediated PI3K/Akt/mTOR Signaling Suppression
Colitis is a major form of inflammatory bowel disease which involved mucosal immune dysfunction. Aloperine is an alkaloid isolated from the shrub Sophora alopecuroides L. and has been recognized as an effective treatment for inflammatory and allergic diseases. The present study aimed to examine the molecular mechanisms underlying aloperine-mediated colitis protection. We found that aloperine treatment improved colitis induced by dextran sodium sulfate (DSS) based on body weight, disease activity index, colonic length, and spleen index. Aloperine also effectively attenuated DSS-induced intestinal inflammation based on the pathological score and myeloperoxidase expression and activity in colon tissues. In addition, aloperine regulated T-cell proportions and promoted Foxp3 expression in the spleens and mesenteric lymph nodes of DSS-induced colitis mice and in the spleens of the Foxp3GFP mice. Aloperine inhibited Jurkat and mouse naïve T-cell apoptosis. Furthermore, aloperine inhibited PI3K/Akt/mTOR signaling and upregulated PP2A expression in the DSS-induced colitis mice and in Jurkat cells, but LB-100 (PP2A inhibitor) resulted in an elevated Akt activity in Jurkat cells, activated T-cells, and human splenic mononuclear cells. Aloperine inhibited T-cell and lymphocyte proliferation, but LB-100 reverse these effects. In conclusion, aloperine regulates inflammatory responses in colitis by inhibiting the PI3K/Akt/mTOR signaling in a PP2A-dependent manner.
Inflammatory bowel disease (IBD) is a familial spontaneous autoimmune disease, but its pathogenesis remains enigmatic. The highest rates of incidence and prevalence of ulcerative colitis (UC) and Crohn’s disease (CD) have been reported in Europe and the USA, and these rates have recently increased 24-fold in China . Moreover, none of the existing drugs are adequately efficient to provide a prominent relief to the patients with IBD . Mucosal immune dysfunction, especially the overexpression of T-cells, plays a major role in IBD pathogenesis . Regulatory T-cells (Tregs) and T helper cell 17 (Th17) are the most abundant CD4+ T-cell subsets in the lamina propria during the steady state [4, 5]. Th17 cells may enhance intestinal inflammation, whereas Tregs might inhibit the inflammatory responses . The differentiation of Tregs is modulated by the expression of the lineage-specific transcription factor forkhead box P3 (Foxp3), which can suppress autoimmune diseases in normal individuals. Tregs regulate the immune system by secreting suppressive cytokines such as tumor growth factor- (TGF-) β and interleukin- (IL-) 10 . PI3K/Akt/mTOR signaling negatively modulates Treg functions and is involved in several diseases including cancer, ischemic disease, and inflammation [8, 9]. An effective inhibitor of the PI3K/Akt/mTOR pathway might contribute to the treatment of IBD.
Previous studies have shown that aloperine downregulates PI3K/Akt/mTOR signaling in HCT116 human colon cancer cells . Our group confirmed that aloperine significantly attenuated ionizing radiation- (IR-) induced PI3K activation . Aloperine is an alkaloid isolated from the shrub Sophora alopecuroides L. and has been recognized as an effective treatment for inflammatory and allergic diseases [11–17]. It has been shown to increase CD4+CD25+ cells and IL-10 levels as well as alleviate inflammation in mice with 2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced colitis .
Protein phosphatase 2A (PP2A) is a multimeric enzyme that contains a scaffolding A subunit, a regulatory B subunit, and a catalytic C subunit . Akt is one of the major substrates of PP2A, which phosphorylates Akt at serine 473. Inhibition of PP2A results in an elevated Akt activity . PP2A has been identified as a key regulator of PI3K/Akt activation and is involved in the development of tumors and autoimmune diseases [20, 21].
Dextran sodium sulfate- (DSS-) induced murine colitis is regarded as a classical model for intestinal inflammation . The aim of the present study was to examine the molecular mechanisms underlying aloperine-mediated colitis protection. This could provide novel insights into the mechanisms of IBD and improve the treatment strategies.
2. Materials and Methods
C57BL/6 mice (10–12 weeks old, equal number of males and females) were purchased from the Hubei Provincial Center for Disease Control and Prevention (Wuhan, China). Twelve-week-old male Foxp3GFP mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed at the Center for Experimental Animals, Tongji Hospital, Huazhong University of Science and Technology, for at least 1 week before any experiment. All experiments were approved by the Institutional Animal Care and Use Committee of Tongji Hospital, Huazhong University of Science and Technology (2015 IACUC: number 595).
2.2. DSS-Induced Colitis and Aloperine Treatment
Experimental colitis was induced by the administration of 3% DSS (molecular weight 3600–5000 kDa, MP Biomedicals, San Francisco, CA, USA) for 7 days, as described previously . Aloperine (purity ≥ 98%, Kmaels, Shanghai, China; catalog number Q1962) was solubilized in saline containing 5% acetic acid . Seventy C57BL/6 mice were randomly divided into five groups (14 mice/group) (Supplementary Figure 1 available online at https://doi.org/10.1155/2017/5706152): (A) negative control (control) group: the mice were intragastrically administered an equivalent volume of 5% acetic acid in saline and provided distilled drinking water for 14 consecutive days; (B) aloperine group (Alo): the mice were intragastrically administered aloperine solution at a dose of 40 mg/kg/day, according to body weight, for 7 consecutive days and simultaneously provided distilled drinking water; (C) aloperine-DSS group (Alo + DSS): the mice were administered aloperine solution for 7 consecutive days with DSS in the drinking water; (D) DSS-aloperine group (DSS + Alo): the mice were provided DSS in the drinking water for the first week and then intragastrically administered aloperine solution during the second week; and (E) DSS group (DSS): the mice were intragastrically administered 5% acetic acid in normal saline for 14 consecutive days and provided DSS in the drinking water for the first week and distilled drinking water during the second week. Subsequently, the mice were sacrificed with sodium pentobarbital on day 14. Serum, spleen, colon, and mesenteric lymph nodes (MLNs) were harvested.
Twelve Foxp3GFP mice were randomly divided into two groups (6 mice/group): (A) Alo group: the mice were intraperitoneally injected with aloperine solution (20 mg/kg body weight) as a volume of 0.1 mL/10 g of body weight once per day for 3 consecutive days, and (B) negative control group: the mice were intraperitoneally injected with an equivalent volume of 5% acetic acid in normal saline. The mice were sacrificed by spinal dislocation on day 4.
2.3. Disease Activity Index (DAI) and Spleen Index (SI)
Each mouse was observed daily, and the DAI was assessed based on the clinical manifestations of diarrhea, bloody stool, and weight loss . The stool consistency was checked for diarrhea, and the feces were screened for blood using a fecal occult blood kit (ABON Biopharm Co. Ltd., Hangzhou, China). The SI was calculated as the ratio of the spleen weight to the body weight on day 14 when the animals were euthanized .
2.4. Histopathological Score and Immunohistochemistry (IHC)
The colon tissues were stained with hematoxylin and eosin (H&E). The degree of colon inflammation was analyzed according to a previously described scoring system . Myeloperoxidase (MPO) was detected by established IHC techniques .
2.5. Measurement of MPO Activity
The MPO activity in the colon or serum was measured using an MPO activity testing kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
2.6. Western Blotting Analysis and Real-Time PCR Reactions
The real-time PCR method has been described in a previous paper . The primers are presented in Table 1. The cells or mouse colon tissues were lysed for protein immunoblotting, as described previously . The membrane was probed with antibodies (1 : 1000 dilution) including PI3K p85, p-PI3K p85, Akt, p-Akt, mTOR, p-mTOR, Bcl-2, Mcl-1, Bax (Cell Signaling Technology, Danvers, MA, USA), PHLPP1, PML, MPO, p-IKBα, β-actin, cleaved caspase-3, Foxp3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), PP2Aa, PP2Ab, and PP2Ac (Protech, Wuhan, China). The intensity of each band was analyzed using the densitometry feature in the ImageJ software (http://rsb.info.nih.gov/ij/).
|IL-17A: interleukin-17A; FOXP3: forkhead box P3; IL-10: interleukin-10; TGF-β: tumor growth factor-β; F: forward; R: reverse.|
2.7. Flow Cytometry
Lymphocytes were isolated from the C57BL/6 mouse spleens and MLNs in single-cell suspensions. The cells were stained with fluorescence-labeled antibodies against CD4-FITC and CD44-APC at 4°C for 30 min. The samples were stained with antibodies against Foxp3-PE (NRRF30, eBioscience Inc., San Diego, CA, USA) at room temperature for 30 min in the dark after using a Foxp3 fixation/permeabilization kit (BD Biosciences, San Diego, CA, USA) . The lymphocytes collected from the Foxp3GFP mouse spleens were stained with fluorescence-labeled antibodies against CD4-PE and CD62L-APC at 4°C for 30 min. Flow cytometry was performed on an LSRII cytometer (BD Biosciences) and analyzed with the FlowJo 7.6 software. Anti-mouse CD4-FITC (GK1.5) and Foxp3-PE (NRRF30) were purchased from eBioscience. CD62L-APC (MEL-14) was purchased from BD Biosciences. CD4-PE (GK1.5) and CD44-APC (IM7) were obtained from BioLegend Inc. (San Diego, CA, USA).
2.8. Preparation of Jurkat Cells for Confocal Imaging
Jurkat cells, an acute T lymphoblastic leukemia cell line, were purchased from Clontech Laboratories Inc. (CA, USA). The cells were cultured with 0.5 mM aloperine for 48 h, followed by staining with a primary antibody against PP2Ab (rabbit, 1 : 100) .
2.9. Mouse Naïve CD4+ T-Cell Isolation and Differentiation
One day before T-cell isolation, culture plates were coated with 5 μg/mL of anti-CD3 and 1 μg/mL of anti-CD28 antibodies in sterile PBS and incubated overnight at 4°C. Lymph nodes and spleens were isolated from 8-week-old C57BL/6 female mice using a mouse naïve T-cell isolation kit (STEMCELL Technologies EasySep™, catalog number 19782, CA, USA). After isolation, the naïve T-cells were seeded into the wells with 20 ng/mL IL-2 for stimulation and collected after 24 h to assess the activation. The remaining cells were stimulated with 20 ng/mL IL-2 and 5 ng/mL TGF-β and collected after 72 h to test their differentiation. Anti-CD3, anti-CD28, IL-2, and TGF-β were purchased from R&D Systems (MN, USA). The Mouse Treg Isolation Kit (STEMCELL Technologies EasySep, catalog number 19852) was used to isolate mouse Tregs.
2.10. Isolation of Spleen Mononuclear Cells
Spleen mononuclear cells were isolated from C57BL/6 mice or healthy volunteers by density gradient centrifugation using a mouse or human lymphocyte separation medium (Dakewe, Shenzhen, China), respectively. Culture plates were coated with 20 ng/mL IL-2, 5 μg/mL anti-CD3, and 1 μg/mL anti-CD28 in sterile PBS overnight at 4°C. On the following day, spleen mononuclear cells were isolated and seeded into the wells for 24 h. Human splenic cells were isolated from healthy donors at the Institute of Organ Transplantation, Tongji Hospital (TJ-IRB20160601).
2.11. Mixed Lymphocyte Reaction
Splenocytes (1 × 105 cells/well) isolated from one C57BL/6 mouse and one BALB/c mouse were mixed and cultured in a 96-well round-bottom microculture plate (Corning Inc., Corning, NY, USA). The splenocytes from the BALB/c mouse were used as allogeneic stimulators and prepared by pretreating the cells (1 × 107 cells/mL) with 50 μg/mL of mitomycin C (Hisun Pharmaceutical Co. Ltd., Hangzhou, China) at 37°C for 30 min. Splenocytes from the C57BL/6 mouse were cultured without stimulatory cells and used as the negative control. Mixed cell cultures treated with 2 μg/mL concanavalin A (ConA) (Sigma, USA) were used as the positive control. The cultures were maintained for 5 days. The cell viability was estimated quantitatively using a Cell Counting Kit-8 assay as described below.
2.12. Cytotoxicity Assay
The cytotoxicity assay was conducted using a Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). The cells were seeded in 96-well plates at a density of 3000 cells/well and cultured with the indicated treatment.
2.13. Cell Culture and Aloperine Treatment
Jurkat cells, mouse naïve T-cells, mouse Tregs, and human spleen mononuclear cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco, Thermo Fisher Biotechnology, Waltham, MA, USA). Aloperine was solubilized in saline containing 0.08% acetic acid.
LB-100 (PP2A inhibitor), wortmannin (PI3K inhibitor), and perifosine (p-Akt inhibitor) were obtained from Selleck Chemicals (Houston, TX, USA).
2.15. Statistical Analysis
Data were analyzed using the GraphPad Prism 5.0 software and presented as the mean ± standard error of mean (SEM). Data were analyzed by one-way analysis of variance (ANOVA) followed by the Tukey post hoc test or independent sample t-test, as appropriate. In all statistical analyses, value < 0.05 was considered statistically significant.
3.1. Alo Treatment Ameliorates the General Symptoms of Murine Colitis
The aloperine solution was administered orally in C57BL/6 mice with DSS-induced acute colitis. On day 7, we observed that the mouse stools were mostly normal in both the control and Alo groups (Figure 1(c)). The classical manifestations of colitis appeared in all the mice in the DSS group, including the most severe liquid or bloody stool, weight loss, and high disease activity index (DAI). In the DSS + Alo and Alo + DSS groups, the body weight first decreased, but took an increasing trend by day 8, and remained higher than that in the DSS group (Figure 1(a)). The DAI in the Alo + DSS and DSS + Alo groups was similar but significantly lower than that in the DSS group (Figure 1(b)).
After 2 weeks, all the mice were euthanatized. The colon length was shortest in the DSS group, indicating severe destruction, while the colon length in the Alo + DSS and DSS + Alo groups was longer (Figure 1(d)). The SI is related to the immunosuppressive functions. All mice in the DSS group developed splenomegaly, but those in the Alo + DSS and DSS + Alo groups were healthier (Figure 1(e)), as shown by lower SI in the Alo + DSS and DSS + Alo groups compared with the DSS group; there were no differences in SI among all other groups.
3.2. Aloperine Alleviates Inflammation and Reduces MPO Activity in Murine Colitis
The DSS group exhibited severe inflammatory responses, including intense infiltration of inflammatory cells into the lamina propria, mucosal edema and erosion, ulcer and crypt distortion, and destroyed placenta percreta. The acute inflammation of the intestinal tracts in both treatment groups was greatly ameliorated, but the effect was slightly greater in the Alo + DSS group (Figure 2(a)). These data suggested that treatment with aloperine might improve murine colitis.
Western blot indicated that DSS increased MPO and p-IKBα protein levels, two specific markers for assessing inflammation, while aloperine inhibited MPO and p-IKBα protein levels (Figure 2(b)). Aloperine also alleviated the interstitial infiltration of neutrophils indicated by MPO expression by IHC staining (Figure 2(c)). In addition, DSS increased the serum and colonic MPO activity, while aloperine suppressed the serum and colonic MPO activity in murine colitis (Figure 2(d)). Thus, we concluded that aloperine effectively attenuated DSS-induced intestinal inflammation.
3.3. Aloperine Regulates the Proportion of Tregs
DSS increased the levels of IL-17A mRNA expression, decreased TGF-β, IL-10, and Foxp3 mRNA expressions, and increased the IL-17A/Foxp3 ratio. IL-17A mRNA expression was decreased after aloperine treatment, especially in the Alo + DSS group. The IL-17A/Foxp3 ratio was found to be lower in the Alo + DSS group than in the DSS group, but there was no difference between the DSS and DSS + Alo groups. The mRNA expressions of the anti-inflammatory cytokines TGF-β (Alo + DSS group only) and IL-10 (Alo + DSS and DSS + Alo groups) were increased, while the expression of Foxp3 did not change, compared with the DSS group (Figure 3(a)).
DSS decreased the frequency of CD4+Foxp3+ T-cells in the spleens and MLNs. Under inflammatory conditions, higher frequencies of CD4+Foxp3+ T-cells in the spleens and MLNs in the Alo + DSS and DSS + Alo groups were observed in the presence of aloperine compared to the DSS group (Figure 3(b)).
Moreover, DSS increased the frequency of CD44+CD4+ T-cells in the spleens and MLNs, while we detected a lower frequency of CD44+CD4+ T-cells in the spleens and MLNs of the mice treated with aloperine (Figures 3(c) and 3(d)). Furthermore, we found higher levels of Foxp3 and CD62L in the Foxp3GFP mice intraperitoneally injected with aloperine for 3 days compared to the control group under normal physiological conditions (Figures 3(e) and 3(f)). Real-time PCR showed that aloperine promoted the expression of Foxp3 and the anti-inflammatory cytokines IL-10 and TGF-β in mouse Tregs. In contrast, the proinflammatory cytokines IL-17A and IL17A/Foxp3 ratio were decreased (Figure 3(g)).
Therefore, we concluded that aloperine alleviated the inflammation in mouse colon and regulated the immune system homeostasis. In addition, aloperine might promote Foxp3+ Tregs and reduce T-cell activation independently from the administration route (intragastric or intraperitoneal).
3.4. Aloperine Inhibits T-Cell Apoptosis
Studies have shown that moderate concentrations of aloperine are effective against tumor cells and safe for normal cell viability [10, 15]. Treatment with aloperine for 24 h enhanced the expression of Bax (0.5 and 1.0 mM) but decreased the expression of Bcl-2 (0.5 and 1.0 mM) and caspase-3 (0.25, 0.5, and 1.0 mM) in Jurkat cells (Figure 4(a)). In addition, we observed that aloperine decreased the Bcl-2 and cleaved caspase-3 levels but raised the expression of Mcl-1 in mouse naïve T-cells (Figure 4(b)).
3.5. Aloperine Suppresses PI3K/Akt/mTOR Signaling In Vitro and In Vivo
Western blotting showed that different aloperine concentrations suppressed the activation of PI3K/Akt/mTOR signaling in Jurkat cells (Supplementary Figure 2A). We cultured the Jurkat cells with aloperine (0.5 mM) alone or in the presence of the PI3K inhibitor wortmannin (10 nM) and the p-Akt inhibitor perifosine (4 μM) for 24 h. This treatment of the Jurkat cells with aloperine in the presence of inhibitors resulted in an enhanced suppressive effect on mTOR, PI3K, and Akt compared to the treatment with aloperine alone (Figure 5(a)). In agreement with this result, significantly lower expressions of the downstream molecules, PI3K p85, Akt, and mTOR, were detected in the colons of mice from the two treatment groups compared to the DSS group (Figure 5(b)).
3.6. PP2A Is a Vital Molecule Mediating the Aloperine-Induced Suppression of PI3K/Akt/mTOR Signaling
Western blotting showed that 1 mM aloperine increased the expression of PP2Ab in Jurkat cells (Supplementary Figure 2B). Confocal microscopy suggested that PP2Ab was translocated from the plasma membrane to the cytoplasm after aloperine treatment (Supplementary Figure 2C). In agreement with these results, we found that DSS decreased PP2A expression in the colon of mice, while aloperine markedly increased PP2A expression in the colons of mice from the Alo + DSS and DSS + Alo groups as compared to the DSS group (Figure 5(c)).
We cultured the Jurkat cells with aloperine (0.5 mM) alone or in the presence of the PP2A inhibitor LB-100 (4 μM) for 24 h. LB-100 reversed aloperine-induced suppression of PI3K/Akt/mTOR signaling (Figure 5(a)). In addition, aloperine suppressed PI3K/Akt/mTOR signaling in mouse naïve T-cells (Figure 6(a)). No difference was observed between the active and inactive human splenic mononuclear cells, suggesting that the human donor cells had been activated (Figure 6(b)). These data suggested that PP2A is involved in the regulatory effect of aloperine on PI3K/Akt/mTOR signaling.
3.7. PP2A Plays a Role in Aloperine-Induced Inhibition of T-Cell and Lymphocyte Proliferation and Promotion the Expression of Foxp3
The mixed lymphocyte reaction (MLR) showed that the alloreactivity-induced proliferation was inhibited by high concentrations of aloperine, while LB-100 reverse this effect (Figure 7(a)). In addition, the CCK-8 assay showed that aloperine decreased the viability of Jurkat and splenic mononuclear cells in both mice and humans (Figures 7(b), 7(c), and 7(d)). LB-100 treatment alleviated the ability of aloperine to inhibit Jurkat cell apoptosis and exhibited a similar effect on primary cells. Surprisingly, both aloperine and LB-100 increased the Foxp3 levels in mouse naïve T-cells and Tregs, compared with aloperine alone (Figures 7(e) and 7(f)).
In the present study, aloperine treatment improved colitis induced by DSS based on body weight, DAI, colon length, and SI. Aloperine also attenuated the inflammation of colitis in mouse based on the pathological score and MPO, which is a specific marker of neutrophil infiltration that is often used to assess disease activity in colitis . Aloperine suppresses PI3K/Akt/mTOR signaling by promoting Foxp3+ Tregs, reducing T-cell activation, and inducing T-cell apoptosis (through increased Bax expression and decreased Bcl-2 and cleaved caspase-3 expression). Tregs inhibit the inflammatory responses in the intestinal mucosa and maintain the immune balance . Moreover, aloperine can also promote the activation of Tregs under normal physiological conditions.
Aloperine may inhibit the excessive immune response by inhibiting the T-cell proliferation and modulating the balance between proinflammatory and anti-inflammatory factors in the intestinal mucosa, as previously observed. Indeed, Yang et al.  showed that aloperine decreases inflammatory pain in mice through the suppression of proinflammatory cytokines. This improved anti-inflammatory balance by aloperine could be a putative mechanism underlying aloperine-mediated protection against colitis. Taken together, we deduced that the most critical effect of aloperine treatment in colitis was blocking the CD44highCD62Llow effector/memory cells and regulating the Treg functions. No differences were observed between the two treatment groups in the proportions of Tregs and effector/memory cells, which indicated that the effects of simultaneous or subsequent aloperine treatments on T-cell differentiation were similar. The T-cells can be divided into two major subsets: naïve and activated T-cells, which include the effector and memory T-cells . The naïve cells are characterized by the CD44lowCD62Lhigh phenotype and become effector T-cells (CD44highCD62Llow) when stimulated by antigens . Aloperine suppressed the production of proinflammatory cytokine IL-17A and declined the IL17A/Foxp3 ratio and effector T-cell proliferation, upregulated the expansion of memory T-cell, and promoted the proliferation of Tregs, thereby inhibiting excessive immune response in the intestine. Our results confirmed that aloperine regulated the immune balance by controlling the proportion and functions of Tregs and relative cytokines, IL-10 and TGF-β.
Aloperine induces G2/M phase cell cycle arrest and apoptosis in human colon cancer cells . PP2A is considered a proapoptotic factor that inhibits cell mitosis through phosphorylation during the cell cycle, mostly during the G2/M phases . Aloperine regulates the expression and location of PP2A and T-cell apoptosis in colitis through increased Bax expression and decreased Bcl-2 and cleaved caspase-3 expression. Indeed, our data indicated that PP2A might be vital in mediating the protective effects of aloperine. This phenomenon indicated that PP2A is differentially regulated with respect to Treg frequency and function. Therefore, aloperine modulates the intestinal immune system through PI3K/Akt/mTOR pathway and PP2A is a vital regulatory protein. We postulated that aloperine induces the apoptosis of T-cells and Jurkat cells and inhibits their proliferation. The inhibition of PP2A abolished the suppressive effect, which might be ascribed as the underlying mechanism for aloperine-attenuated murine colitis.
The annihilation of PP2A might compromise Treg functions. PP2A knockout mice were confirmed to be with lymphoproliferative and autoimmune disorders, as shown by greater Treg cell frequency in the spleen and lymph nodes . In addition, PP2A has been shown to enhance the inflammatory effects of a number of compounds [36, 37] and PP2A activation attenuates inflammation in animal models [38, 39]. These results were consistent with the present study, wherein we showed that PP2A expression declined in colitis and LB-100 increased the expression of Foxp3 in mouse naïve T-cells and Tregs. Conversely, a previous study demonstrated that mice fed DSS for 3–12 weeks exhibited PP2A methylation, which might cause inflammation . The change in methylation may be detected after an extended period, and this discrepancy might be due to the different durations of treatments in animal models as our experiment lasted only 2 weeks and represented an acute inflammation model.
We demonstrated that aloperine suppressed PI3K/AkT/mTOR signaling, a pathway that positively regulates T-cell functions [9, 41, 42]. This phenomenon may be a pivotal mechanism underlying the aloperine-mediated therapeutic effect on colitis. We used in vivo and in vitro experiments to confirm that aloperine suppressed PI3K/Akt/mTOR signaling and promoted Treg differentiation and activation in mice; similar results were obtained in human splenic cells. The inhibition of the PI3K/Akt/mTOR signaling has been shown to have benefits in a number of inflammatory condition [43–45]. The PI3K/Akt/mTOR signaling pathway negatively modulates the functions of Tregs; the PI3K activity is most abundant among proinflammatory cells within the stroma . PP2A might inactivate PI3K and abrogate the suppressive capacity of Treg cells. The present study suggests that PP2A is upstream of PI3K/Akt/mTOR, but the mechanism which is the relationship between PI3K/Akt/mTOR pathway and PP2A is not yet elucidated. Furthermore, PP2A is a signaling phosphatase that has been implicated in the regulation of Akt activities [47, 48]. PP2A may directly interact with Akt that mediates the suppressive effect of aloperine on PI3K signaling. In order to determine whether PP2A is a direct target of aloperine, further studies are needed. In addition, the relationships among Tregs, PI3K/Akt/mTOR pathway, and PP2A need to be further studied.
The literature proposes two routes for aloperine administration: intragastric administration and intraperitoneal injection [11, 12]. In the first stage of the study, we found that intragastric administration of aloperine could promote the expression of Treg in DSS-induced colitis mouse model. Therefore, in the second stage, the other route was tried to verify the effect of aloperine on the expression of Treg in the Foxp3GFP mice. We agree that we could have used the same route in both parts of the experiment, but a confirmation that both routes worked was wanted. As for the dose, our previous pilot experiments (data not shown) suggested that a 20 mg/kg dose was enough when the intraperitoneal route was used. Indeed, when using the intragastric route, it is probable that not all aloperine is absorbed by the intestine. This will have to be explored in future studies.
Aloperine regulates the inflammatory responses in colitis by inhibiting the PI3K/Akt/mTOR signaling in a PP2A-dependent manner.
Conflicts of Interest
The authors declare no conflicts of interest.
Xiaoxia Fu, Fei Sun, and Faxi Wang contributed equally to this work.
This work was supported by the National Natural Science Foundation of China (81570009, 81273237, and 81573932), the Provincial Natural Science Foundation of Guangdong Province (2015A030313513), and the Science and Technology Innovation Fund of Guangdong Medical College (STIF201110 and B2012078).
Supplementary Figure 1. Schematic illustration of the C57BL/6 mice randomly divided into five groups. i.g.: intragastric administration; DSS: Dextran sodium sulfate. Supplementary Figure 2. Effects of aloperine on PI3K/Akt/mTOR signaling and PP2Ab in Jurkat cells. (A) Western blot analysis of PI3K/Akt/mTOR signaling in Jurkat cells after 24 h treatment with different concentrations (0.25, 0.5, or 1 mM). (B) Western blot analysis of PHLPP1, PML, and PP2Ab after 24 h treatment with different concentrations (0.25, 0.5, or 1 mM). (C) Immunofluorescent staining of PP2Ab in Jurkat cells after treatment with 0.5 mM aloperine for 48 h.
- J. B. Kirsner, Inflammatory Bowel Disease, Saunders, Philadelphia, 2000.
- M. Salaga, H. Zatorski, M. Sobczak, C. Chen, and J. Fichna, “Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review,” Current Treatment Options in Oncology, vol. 15, no. 3, pp. 405–420, 2014.
- B. Mirlekar, S. Ghorai, M. Khetmalas, R. Bopanna, and S. Chattopadhyay, “Nuclear matrix protein SMAR1 control regulatory T-cell fate during inflammatory bowel disease (IBD),” Mucosal Immunology, vol. 8, no. 6, pp. 1184–1200, 2015.
- A. Y. Rudensky, “Regulatory T cells and Foxp3,” Immunological Reviews, vol. 241, no. 1, pp. 260–268, 2011.
- E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006.
- T. Feng, H. Qin, L. Wang, E. N. Benveniste, C. O. Elson, and Y. Cong, “Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production,” Journal of Immunology, vol. 186, no. 11, pp. 6313–6318, 2011.
- Y. Feng, A. Arvey, T. Chinen, J. van der Veeken, G. Gasteiger, and A. Y. Rudensky, “Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus,” Cell, vol. 158, no. 4, pp. 749–763, 2014.
- A. Huynh, M. DuPage, B. Priyadharshini et al., “Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability,” Nature Immunology, vol. 16, no. 2, pp. 188–196, 2015.
- H. Chi, “Regulation and function of mTOR signalling in T cell fate decisions,” Nature Reviews. Immunology, vol. 12, no. 5, pp. 325–338, 2012.
- L. Zhang, Y. Zheng, H. Deng, L. Liang, and J. Peng, “Aloperine induces G2/M phase cell cycle arrest and apoptosis in HCT116 human colon cancer cells,” International Journal of Molecular Medicine, vol. 33, no. 6, pp. 1613–1620, 2014.
- S. Hu, Y. Zhang, M. Zhang et al., “Aloperine protects mice against ischemia reperfusion (IR)-induced renal injury by regulating PI3K/AKT/mTOR signaling and AP-1 activity,” Molecular Medicine, vol. 21, no. 1, p. 912, 2015.
- Y. Q. Xu, S. J. Jin, N. Liu et al., “Aloperine attenuated neuropathic pain induced by chronic constriction injury via anti-oxidation activity and suppression of the nuclear factor kappa B pathway,” Biochemical and Biophysical Research Communications, vol. 451, no. 4, pp. 568–573, 2014.
- X. Y. Yuan, H. M. Ma, R. Z. Li, R. Y. Wang, W. Liu, and J. Y. Guo, “Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice,” European Journal of Pharmacology, vol. 658, no. 2-3, pp. 263–269, 2011.
- W. C. Lin and J. Y. Lin, “Five bitter compounds display different anti-inflammatory effects through modulating cytokine secretion using mouse primary splenocytes in vitro,” Journal of Agricultural and Food Chemistry, vol. 59, no. 1, pp. 184–192, 2011.
- H. Wang, S. Yang, H. Zhou et al., “Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms,” Journal of Hematology & Oncology, vol. 8, p. 26, 2015.
- Y. Zhou, H. Wang, L. Liang, W. C. Zhao, Y. Chen, and H. Z. Deng, “Total alkaloids of Sophora alopecuroides increases the expression of CD4+ CD25+ Tregs and IL-10 in rats with experimental colitis,” The American Journal of Chinese Medicine, vol. 38, no. 2, pp. 265–277, 2010.
- Z. Dang, L. Zhu, W. Lai et al., “Aloperine and its derivatives as a new class of HIV-1 entry inhibitors,” ACS Medicinal Chemistry Letters, vol. 7, no. 3, pp. 240–244, 2016.
- U. S. Cho and W. Xu, “Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme,” Nature, vol. 445, no. 7123, pp. 53–57, 2007.
- P. Pandey, P. Seshacharyulu, S. Das et al., “Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway,” British Journal of Cancer, vol. 108, no. 12, pp. 2590–2600, 2013.
- A. Persad, G. Venkateswaran, L. Hao et al., “Active β-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A,” Genes & Cancer, vol. 7, no. 11-12, pp. 368–382, 2016.
- N. T. Vasudevan, M. L. Mohan, M. K. Gupta, A. K. Hussain, and S. V. Naga Prasad, “Inhibition of protein phosphatase 2A activity by PI3Kgamma regulates beta-adrenergic receptor function,” Molecular Cell, vol. 41, no. 6, pp. 636–648, 2011.
- Y. Chen, J. M. Si, W. L. Liu et al., “Induction of experimental acute ulcerative colitis in rats by administration of dextran sulfate sodium at low concentration followed by intracolonic administration of 30% ethanol,” Journal of Zhejiang University. Science. B, vol. 8, no. 9, pp. 632–637, 2007.
- A. Hartog, F. N. Belle, J. Bastiaans et al., “A potential role for regulatory T-cells in the amelioration of DSS induced colitis by dietary non-digestible polysaccharides,” The Journal of Nutritional Biochemistry, vol. 26, no. 3, pp. 227–233, 2015.
- J. Togawa, H. Nagase, K. Tanaka et al., “Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance,” Journal of Gastroenterology and Hepatology, vol. 17, no. 12, pp. 1291–1298, 2002.
- S. Wang, Y. Xie, X. Yang et al., “Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice,” Parasites & Vectors, vol. 9, p. 6, 2016.
- P. Ye, F. H. Rodriguez, S. Kanaly et al., “Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense,” The Journal of Experimental Medicine, vol. 194, no. 4, pp. 519–527, 2001.
- S. Zhang, J. W. Lv, P. Yang et al., “Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling,” The American Journal of Pathology, vol. 181, no. 3, pp. 937–946, 2012.
- Y. Yao, Y. Wang, Z. Zhang et al., “Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production,” Molecular Therapy, vol. 24, no. 5, pp. 915–925, 2016.
- X. Rao, J. Zhong, S. Zhang et al., “Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury,” Circulation, vol. 123, no. 25, pp. 2964–2974, 2011.
- Y. Zhu, Y. Feng, H. Liu et al., “CD4+CD29+T cells are blamed for the persistent inflammatory response in ulcerative colitis,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 3, pp. 2627–2637, 2015.
- Y. Yang, S. J. Jin, H. L. Wang et al., “Effects of aloperine on acute and inflammatory pain models in mice,” Scandinavian Journal of Pain, vol. 8, pp. 28–34, 2015.
- J. R. Lees and D. L. Farber, “Generation, persistence and plasticity of CD4 T-cell memories,” Immunology, vol. 130, no. 4, pp. 463–470, 2010.
- D. Yan, J. Farache, M. Mingueneau, D. Mathis, and C. Benoist, “Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 48, pp. 14942–14947, 2015.
- F. R. Gong, M. Y. Wu, M. Shen et al., “PP2A inhibitors arrest G2/M transition through JNK/Sp1-dependent down-regulation of CDK1 and autophagy-dependent up-regulation of p21,” Oncotarget, vol. 6, no. 21, pp. 18469–18483, 2015.
- S. A. Apostolidis, N. Rodriguez-Rodriguez, A. Suarez-Fueyo et al., “Phosphatase PP2A is requisite for the function of regulatory T cells,” Nature Immunology, vol. 17, no. 5, pp. 556–564, 2016.
- M. M. Rahman, N. N. Rumzhum, P. M. Hansbro et al., “Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells,” Cellular Signalling, vol. 28, no. 4, pp. 325–334, 2016.
- A. R. Clark and J. L. Dean, “The control of inflammation via the phosphorylation and dephosphorylation of tristetraprolin: a tale of two phosphatases,” Biochemical Society Transactions, vol. 44, no. 5, pp. 1321–1337, 2016.
- W. M. McHugh, W. W. Russell, A. J. Fleszar et al., “Protein phosphatase 2A activation attenuates inflammation in murine models of acute lung injury,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 311, no. 5, pp. L903–L912, 2016.
- S. Yun, M. Budatha, J. E. Dahlman et al., “Interaction between integrin alpha5 and PDE4D regulates endothelial inflammatory signalling,” Nature Cell Biology, vol. 18, no. 10, pp. 1043–1053, 2016.
- L. Schwartz, M. Abolhassani, M. Pooya et al., “Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A,” American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 295, no. 5, pp. G934–G941, 2008.
- A. T. Waickman and J. D. Powell, “mTOR, metabolism, and the regulation of T-cell differentiation and function,” Immunological Reviews, vol. 249, no. 1, pp. 43–58, 2012.
- Y. C. Lo, C. F. Lee, and J. D. Powell, “Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection,” Current Opinion in Organ Transplantation, vol. 19, no. 4, pp. 363–371, 2014.
- A. W. Thomson, H. R. Turnquist, and G. Raimondi, “Immunoregulatory functions of mTOR inhibition,” Nature Reviews. Immunology, vol. 9, no. 5, pp. 324–337, 2009.
- I. N. Srivastava, J. Shperdheja, M. Baybis, T. Ferguson, and P. B. Crino, “mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy,” Neurobiology of Disease, vol. 85, pp. 144–154, 2016.
- T. Weichhart, G. Costantino, M. Poglitsch et al., “The TSC-mTOR signaling pathway regulates the innate inflammatory response,” Immunity, vol. 29, no. 4, pp. 565–577, 2008.
- M. W. Khan, A. Keshavarzian, E. Gounaris et al., “PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer,” Clinical Cancer Research, vol. 19, no. 9, pp. 2342–2354, 2013.
- J. M. Beaulieu, T. D. Sotnikova, S. Marion, R. J. Lefkowitz, R. R. Gainetdinov, and M. G. Caron, “An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior,” Cell, vol. 122, no. 2, pp. 261–273, 2005.
- Y. Liao and M. C. Hung, “Physiological regulation of Akt activity and stability,” American Journal of Translational Research, vol. 2, no. 1, pp. 19–42, 2010.
Copyright © 2017 Xiaoxia Fu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.